文献速递肿瘤 PET/CT

[18F]FAPI-42 PET/CT用于特发性肺纤维化预后评估:与[18F]FDG PET/CT的前瞻性头对头比较

[18F]FAPI-42 PET/CT for prognostic assessment in idiopathic pulmonary fibrosis: a prospective head-to-head comparison with [18F]FDG PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-07-30

结果显示wlTU-FAPI与疾病严重程度及不良结局的关联强于wlTU-FDG,且为死亡或肺移植的独立预测因素。

要点

  • wlTU-FAPI在GAP II-III期高于I期,wlTU-FDG无此差异。
  • wlTU-FAPI与DLCO% pred和FVC% pred均相关,wlTU-FDG仅与DLCO% pred相关。
  • wlTU-FAPI为死亡或肺移植的独立预测因素(HR 4.62),wlTU-FDG无预测价值。

核心结论

  • [18F]FAPI-42 PET/CT是预测IPF临床结局的有前景的无创影像生物标志物,与[18F]FDG PET/CT相比与疾病严重程度和不良临床结局关联更强。

研究设计与样本

  • 主要终点为全因死亡或肺移植复合终点,采用Kaplan-Meier和Cox比例风险模型分析;中位随访19(17.0-20.0)个月,48例可评估。

主要发现

  • wlTU-FAPI在GAP II和III期高于I期(3733 vs. 2985,P=0.039),wlTU-FDG无差异(2247 vs. 2176,P=0.911)。
  • wlTU-FAPI与DLCO% pred负相关(rs=-0.65,P<0.001),wlTU-FDG亦负相关(rs=-0.54,P<0.001)。
  • wlTU-FAPI与FVC% pred负相关(rs=-0.44,P=0.002),wlTU-FDG无相关(P=0.291)。
  • 免疫组化证实纤维母细胞灶中FAP高表达、GLUT-1低表达(n=4)。
  • 13例达到复合终点者wlTU-FAPI更高(3728 vs. 2888,P=0.028),wlTU-FDG无差异(2261 vs. 2139,P=0.231)。

关键数值与推荐

  • 多因素Cox回归中wlTU-FAPI为死亡或肺移植的独立预测因素(每增加1000单位HR=4.62,95%CI 1.62-13.22,P=0.004),wlTU-FDG无预测价值(P=0.782)。
  • Kaplan-Meier显示wlTU-FAPI有预后价值(cutoff=2865,P=0.018),wlTU-FDG无统计学意义(cutoff=2036,P=0.660)。

临床怎么用

  • 在IPF患者中可考虑使用[18F]FAPI-42 PET/CT全肺总摄取进行无创预后评估,其与疾病严重程度和不良结局的关联优于[18F]FDG PET/CT。

局限性

  • 研究结论需在更大规模、更多样化的IPF人群中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This prospective study aimed to compare the prognostic value of [18F]FAPI-42 (fibroblast activation protein inhibitor) and [18F]FDG PET/CT in patients with idiopathic pulmonary fibrosis (IPF). METHODS: Fifty-two patients with IPF underwent dual-tracer PET/CT. Whole-lung total uptake (wlTU) was quantified for [18F]FAPI-42 and [18F]FDG. PET parameters were correlated with percent predicted forced vital capacity (FVC% pred), percent predicted diffusing capacity for carbon monoxide (DLCO% pred), and the Gender-Age-Physiology (GAP) stage. Immunohistochemical staining (IHC) for FAP and glucose transporter 1 (GLUT-1) was performed (n = 4). The primary endpoint was a composite of all-cause death or lung transplantation (LuTx), analyzed using Kaplan-Meier and Cox proportional hazards models. RESULTS: In patients with IPF, the median wlTU-FAPI was higher in GAP stage II and III than in GAP stage I (3733 vs. 2985, P = 0.039), whereas wlTU-FDG was not (2247 vs. 2176, P = 0.911). Furthermore, wlTU-FAPI and wlTU-FDG were negatively correlated with DLCO% pred (rs = -0.65, P < 0.001; rs = -0.54, P < 0.001). Notably, wlTU-FAPI was also correlated with FVC% pred (rs = -0.44, P = 0.002), whereas wlTU-FDG did not (P = 0.291). IHC confirmed high FAP and low GLUT-1 expression in fibroblast foci (n = 4). During a median follow-up of 19 (17.0-20.0) months (n = 48), the 13 patients reached the composite endpoint exhibited higher median wlTU-FAPI (3728 vs. 2888, P = 0.028). Conversely, no significant difference was observed for wlTU-FDG (2261 vs. 2139, P = 0.231). In multivariable Cox regression analysis, wlTU-FAPI emerged as an independent predictor of death or LuTx (hazard ratio [HR] per 1000-unit increase, 4.62; 95% CI, 1.62-13.22; P = 0.004), wheras wlTU-FDG did not (P = 0.782). Kaplan-Meier also demonstrated the prognostic value of wlTU-FAPI (cutoff = 2865, P = 0.018), whereas wlTU-FDG was not significant (cutoff = 2036, P = 0.660). CONCLUSION: [18F]FAPI-42 PET/CT is a promising noninvasive imaging biomarker for predicting clinical outcomes in IPF. Compared with [18F]FDG PET/CT, [18F]FAPI-42 demonstrated stronger associations with disease severity and adverse clinical outcomes in this prospective cohort. These findings warrant further validation in larger and more diverse IPF populations.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Fang Q, Hou P, Xia S, et al. [18F]FAPI-42 PET/CT for prognostic assessment in idiopathic pulmonary fibrosis: a prospective head-to-head comparison with [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2026. PMID: 42530577. doi:10.1007/s00259-026-08094-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。